Vaccine therapy for malignant glioma is advancing, with calls for expedited approvals to treat this aggressive brain cancer. The approach has potential to save lives and is part of efforts for rare disease treatments. Early results indicate effectiveness without traditional chemo or radiation.
Trial Insights
The therapy targets tumor reduction through immune activation, with focus on safety for various patient groups.
Next Phases
Expansion to pediatric testing and broader applications in oncology.